Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2020 Jul 2;19(8):1635–1641.e1. doi: 10.1016/j.cgh.2020.06.047

Table 4.

CRC risk assessment and screening completion (excluding patients up-to-date with screening according to EHR); n = 1,172

Control (n = 585) Incentive (n = 587) P-value
Risk assessment; n, % (95% CI) 122, 20.9 (17.6, 24.1) 180, 30.7 (26.9, 34.4)1 <.001
 Up-to-date on CRC screening, n (%) 53 (9.1) 90 (15.2) -
 CRC screening-eligible; n, % (95% CI) 69, 11.8 (9.2, 14.4) 89, 15.2 (12.3, 18.1)2 .09
 Family History of CRC, n (%) 18 (3.1) 21 (3.6) -
Colonoscopy scheduling (3 months); n, % (95% CI) 9, 1.5 (.5, 2.5) 17, 2.9 (1.5, 4.3)1 .11
Colonoscopy completion (3 months); n, % (95% CI) 5, .9 (.1, 1.6) 11, 1.9 (.8, 3.0) .13
Colonoscopy completion (6 months); n, % (95% CI) 7, 1.2 (.3, 2.1) 11, 1.9 (.8, 3.0) .35
1

p-value less than .05 for statistical significance

2

One participant who was not up-to-date but did not meet age criteria for screening eligibility is not included in counts for “screening eligible”